Evidence map›Paper›PMID 38315730›Full record

ArticlePLoS genetics2024

CRISPR screen for protein inclusion formation uncovers a role for SRRD in the regulation of intermediate filament dynamics and aggresome assembly.

Katelyn M Sweeney, Sapanna Chantarawong, Edward M Barbieri, Greg Cajka, Matthew Liu, Lynn Spruce, Hossein Fazelinia, Bede Portz, Katie Copley, Tomer Lapidot and 6 more

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Unlocking Disease-Modifying Treatments for TDP-43-Mediated Neurodegeneration.BioEssays : news and reviews in molecular, cellular and developmental biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Katelyn M SweeneyCenter for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0001-6659-8859
Sapanna ChantarawongCenter for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.ORCID 0009-0004-3169-2625
Edward M BarbieriDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0001-9059-6773
Greg CajkaCenter for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0002-7537-8310
Matthew LiuCenter for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0002-5004-9182
Lynn SpruceProteomics Core Facility, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.
Hossein FazeliniaProteomics Core Facility, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.
Bede PortzDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Katie CopleyDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Tomer LapidotCenter for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.
Lauren DuhamelCenter for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.
Phoebe GreenwaldCenter for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.ORCID 0009-0006-0567-9755
Naseeb SaidaDepartment of Biochemistry, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Reut ShalgiDepartment of Biochemistry, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
James ShorterDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0001-5269-8533
Ophir ShalemCenter for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0002-2267-0801
Children's Hospital of Philadelphia · USUniversity of Pennsylvania · USTechnion – Israel Institute of Technology · IL

Funding

Defining the mechanistic basis of a prion disaggregaseR01GM099836 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI SHORTER, JAMES · 2013 to 2024
$3.9M
Direct and rapid control of proteins at scaleDP2GM137416 · NIGMS · CHILDREN'S HOSP OF PHILADELPHIA · PI SHALEM, OPHIR · 2019 to 2022
$2.8M
Programming human protein disaggregases against FTDR21AG065854 · NIA · UNIVERSITY OF PENNSYLVANIA · PI SHORTER, JAMES · 2020 to 2020
$446k
Dissecting the mechanisms that underlie mislocalization and aggregation of RNA binding proteins in neurodegenerative diseasesR03NS111447 · NINDS · CHILDREN'S HOSP OF PHILADELPHIA · PI SHALEM, OPHIR · 2019 to 2019
$352k
Synthetic Reconstruction of Human Chaperone Networks in Yeast Models of NeurodegenerationK99AG075242 · NIA · UNIVERSITY OF PENNSYLVANIA · PI BARBIERI, EDWARD MATTHEW · 2023 to 2024
$231k
Programming Human Chaperone Systems Against Neurodegenerative DiseaseF32NS108598 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI BARBIERI, EDWARD MATTHEW · 2019 to 2021
$193k
Developing RNA therapeutics for TDP-43 proteinopathy in ALS/FTDF31NS129101 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI COPLEY, KATIE ELIZABETH · 2022 to 2024
$131k
Mechanistic dissection of novel regulators of TDP-43 aggregation identified in a genome-wide CRISPR-Cas9 knockout screenF31NS116999 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI SWEENEY, KATELYN · 2020 to 2022
$113k
NIA NIH HHS K99 AG075242NIA NIH HHS R21 AG065854NIGMS NIH HHS DP2 GM137416NIGMS NIH HHS R01 GM099836NINDS NIH HHS F31 NS116999NINDS NIH HHS F31 NS129101NINDS NIH HHS F32 NS108598NINDS NIH HHS R03 NS111447
6 · The paper itself

Abstract

The presence of large protein inclusions is a hallmark of neurodegeneration, and yet the precise molecular factors that contribute to their formation remain poorly understood. Screens using aggregation-prone proteins have commonly relied on downstream toxicity as a readout rather than the direct formation of aggregates. Here, we combined a genome-wide CRISPR knockout screen with Pulse Shape Analysis, a FACS-based method for inclusion detection, to identify direct modifiers of TDP-43 aggregation in human cells. Our screen revealed both canonical and novel proteostasis genes, and unearthed SRRD, a poorly characterized protein, as a top regulator of protein inclusion formation. APEX biotin labeling reveals that SRRD resides in proximity to proteins that are involved in the formation and breakage of disulfide bonds and to intermediate filaments, suggesting a role in regulation of the spatial dynamics of the intermediate filament network. Indeed, loss of SRRD results in aberrant intermediate filament fibrils and the impaired formation of aggresomes, including blunted vimentin cage structure, during proteotoxic stress. Interestingly, SRRD also localizes to aggresomes and unfolded proteins, and rescues proteotoxicity in yeast whereby its N-terminal low complexity domain is sufficient to induce this affect. Altogether this suggests an unanticipated and broad role for SRRD in cytoskeletal organization and cellular proteostasis.

Indexed as

Clustered Regularly Interspaced Short Palindromic RepeatsIntermediate FilamentsCytoskeletonHumansInclusion Bodies

Identifiers

PMID38315730
PMCPMC10868785
OpenAlexW4391528522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.